Acknowledgements
Breast Cancer, Cancer
ONCOLOGY, BREAST CANCER, CANCER
NeoALTTO is a BIG and SOLTI led trial. CALGB is now part of the Alliance for Clinical Trials in Oncology. Related to the NeoALTTO trial, research reported in this publication was supported by the Fondation contre le cancer, the Breast Cancer Research Foundation, Association Jules Bordet, and the Belgian Fonds National de la Recherche Scientifique (F.R.S-FNRS). Related to the CALGB 40601 trial, research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882, and U24CA196171 (to the Alliance for Clinical Trials in Oncology), UG1CA233180, UG1CA233337, UG1CA233373, R01-CA229409, Breast Cancer Research Foundation. The conduct of the NeoALTTO study was funded by GlaxoSmithKline and later Novartis. The RNA sequencing in NeoALTTO, on which part of the analyses described in this manuscript are based, was funded by GlaxoSmithKline. Both trials received support from GlaxoSmithKline, who provided the study drug. For part of the analysis, computational resources have been provided by the Consortium des Équipements de Calcul Intensif (CÉCI), funded by the Fonds de la Recherche Scientifique de Belgique (F.R.S.-FNRS) under Grant No. 2.5020.11 and by the Walloon Region. M.R. was supported by Télévie and the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS) and by Fondation Rose et Jean Hoguet. R.S. is supported by the Breast Cancer Research Foundation (BCRF, grant nr. 17-194). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.